MA42250B1 - Conjugués d'anticorps à cystéine modifiée - Google Patents
Conjugués d'anticorps à cystéine modifiéeInfo
- Publication number
- MA42250B1 MA42250B1 MA42250A MA42250A MA42250B1 MA 42250 B1 MA42250 B1 MA 42250B1 MA 42250 A MA42250 A MA 42250A MA 42250 A MA42250 A MA 42250A MA 42250 B1 MA42250 B1 MA 42250B1
- Authority
- MA
- Morocco
- Prior art keywords
- conjugates
- cysteine
- modified
- modified antibody
- antibody conjugates
- Prior art date
Links
- 229940127121 immunoconjugate Drugs 0.000 title 1
- 239000011230 binding agent Substances 0.000 abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 abstract 2
- 239000002254 cytotoxic agent Substances 0.000 abstract 2
- 231100000599 cytotoxic agent Toxicity 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68035—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a pyrrolobenzodiazepine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
L'invention concerne de nouveaux conjugués constitués d'un agent de liaison cellulaire et d'un agent cytotoxique, où l'agent de liaison cellulaire (cba) est lié de manière covalente à l'agent cytotoxique par l'intermédiaire d'une cys modifiée, telle qu'une cys modifiée au niveau du domaine ch3 de la chaîne lourde, à une position correspondant à la position 442 en numérotation eu/ou (ou c442) sur un cba de type anticorps. L'invention porte également sur des méthodes de préparation des conjugués de la présente invention. L'invention concerne, en outre, une composition et des méthodes utilisables pour inhiber une croissance cellulaire anormale ou traiter un trouble prolifératif chez le mammifère à l'aide des conjugués de l'invention.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562186254P | 2015-06-29 | 2015-06-29 | |
US201662338245P | 2016-05-18 | 2016-05-18 | |
US15/195,269 US10898579B2 (en) | 2015-06-29 | 2016-06-28 | Conjugates of cysteine engineered antibodies |
Publications (2)
Publication Number | Publication Date |
---|---|
MA42250A MA42250A (fr) | 2018-05-02 |
MA42250B1 true MA42250B1 (fr) | 2020-11-30 |
Family
ID=56409216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA42250A MA42250B1 (fr) | 2015-06-29 | 2016-06-28 | Conjugués d'anticorps à cystéine modifiée |
Country Status (24)
Country | Link |
---|---|
US (2) | US10898579B2 (fr) |
EP (2) | EP3313845B1 (fr) |
JP (4) | JP6843080B2 (fr) |
KR (1) | KR20180021176A (fr) |
CN (2) | CN113769108A (fr) |
AR (1) | AR106013A1 (fr) |
AU (2) | AU2016285929B2 (fr) |
CA (1) | CA2988806A1 (fr) |
CY (1) | CY1123606T1 (fr) |
DK (1) | DK3313845T3 (fr) |
ES (1) | ES2832527T3 (fr) |
HK (1) | HK1254782A1 (fr) |
HR (1) | HRP20201790T1 (fr) |
HU (1) | HUE052616T2 (fr) |
LT (1) | LT3313845T (fr) |
MA (1) | MA42250B1 (fr) |
MD (1) | MD3313845T2 (fr) |
PL (1) | PL3313845T3 (fr) |
PT (1) | PT3313845T (fr) |
RS (1) | RS61050B1 (fr) |
RU (1) | RU2733740C2 (fr) |
SI (1) | SI3313845T1 (fr) |
TW (2) | TW202146057A (fr) |
WO (1) | WO2017004025A1 (fr) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10077313B2 (en) | 2015-06-29 | 2018-09-18 | Immunogen, Inc. | Anti-CD123 antibodies and conjugates and derivatives thereof |
WO2017091745A1 (fr) | 2015-11-25 | 2017-06-01 | Immunogen, Inc. | Formulations pharmaceutiques et leurs procédés d'utilisation |
KR20230133935A (ko) | 2016-11-23 | 2023-09-19 | 이뮤노젠 아이엔씨 | 벤조다이아제핀 유도체의 선택적인 설폰화 |
EP3558391B1 (fr) | 2016-12-23 | 2022-02-02 | Immunogen, Inc. | Immunoconjugués ciblant l'adam9 et leurs méthodes d'utilisation |
WO2018183494A1 (fr) | 2017-03-31 | 2018-10-04 | Immunogen, Inc. | Conjugués anticorps-médicament ciblant cd19 |
KR20200056396A (ko) | 2017-09-22 | 2020-05-22 | 이뮤노젠 아이엔씨 | 양이온 교환 크로마토그래피를 이용한 삼중-경쇄 항체 분리 |
US11628223B2 (en) | 2017-09-29 | 2023-04-18 | Daiichi Sankyo Company, Limited | Antibody-drug conjugates comprising substituted benzo[e]pyrrolo[1,2-α][1,4]diazepines |
TW202029980A (zh) | 2018-10-26 | 2020-08-16 | 美商免疫遺傳股份有限公司 | E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途 |
US20200157228A1 (en) | 2018-10-30 | 2020-05-21 | Immunogen, Inc. | Methods of treatment using anti-cd123 immunoconjugates |
US10913713B2 (en) * | 2018-11-12 | 2021-02-09 | Immunogen, Inc. | Methods of preparing cytotoxic benzodiazepine derivatives |
CA3119358A1 (fr) * | 2018-11-12 | 2020-05-22 | Immunogen, Inc. | Procedes de preparation de derives de benzodiazepine cytotoxiques |
AU2019379418A1 (en) | 2018-11-14 | 2021-06-03 | Daiichi Sankyo Company, Limited | Anti-CDH6 antibody-pyrrolobenzodiazepine derivative conjugate |
AU2020240310A1 (en) * | 2019-03-21 | 2021-10-07 | Immunogen, Inc. | Methods of preparing cell-binding agent-drug conjugates |
CA3134403A1 (fr) | 2019-03-25 | 2020-10-01 | Daiichi Sankyo Company, Limited | Conjugue anticorps anti-her2/derive de pyrrolobenzodiazepine |
JPWO2020196474A1 (fr) | 2019-03-25 | 2020-10-01 | ||
US20220168438A1 (en) | 2019-03-27 | 2022-06-02 | Daiichi Sankyo Company, Limited | Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor |
CN113853217A (zh) | 2019-04-29 | 2021-12-28 | 伊缪诺金公司 | 包含抗cd123免疫缀合物的治疗组合 |
AU2021338014A1 (en) | 2020-09-02 | 2023-03-09 | Daiichi Sankyo Company, Limited | Novel endo-β-N-acetylglucosaminidase |
AU2022207708A1 (en) | 2021-01-13 | 2023-07-27 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
IL312728A (en) | 2021-11-30 | 2024-07-01 | Daiichi Sankyo Co Ltd | Antibodies masked in protease-wells |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
CA2076465C (fr) | 1992-03-25 | 2002-11-26 | Ravi V. J. Chari | Conjugues agents de liaison cellulaire d'analogues et de derives de cc-1065 |
GB9422383D0 (en) * | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
JP2003514903A (ja) | 1999-11-24 | 2003-04-22 | イムノージェン インコーポレーテッド | タキサンを含有する細胞傷害薬とその治療への利用 |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
CA2494074A1 (fr) | 2002-08-02 | 2004-02-12 | Immunogen, Inc. | Agents cytotoxiques renfermant des nouveaux taxanes puissants et utilisation therapeutique de ceux-ci |
AU2003259163B2 (en) | 2002-08-16 | 2008-07-03 | Immunogen, Inc. | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
JP5354835B2 (ja) | 2002-11-07 | 2013-11-27 | イミュノジェン・インコーポレーテッド | 抗cd33抗体、及びそれを用いた急性骨髄性白血病の治療方法 |
CN101239190B (zh) * | 2003-01-27 | 2013-09-25 | 恩多塞特公司 | 维生素受体结合递药缀合物 |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
AU2005218642B2 (en) | 2004-03-02 | 2011-04-28 | Seagen Inc. | Partially loaded antibodies and methods of their conjugation |
BRPI0510883B8 (pt) | 2004-06-01 | 2021-05-25 | Genentech Inc | composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação |
ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
EP1817341A2 (fr) | 2004-11-29 | 2007-08-15 | Seattle Genetics, Inc. | Anticorps et immunoconjugues mis au point |
US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
EP2446904B1 (fr) | 2006-05-30 | 2015-04-29 | Genentech, Inc. | Anti-CD22 anticorps, immuno-conjugués et utilisations associées |
CN101802015B (zh) | 2007-03-29 | 2015-05-06 | 根马布股份公司 | 双特异性抗体及其制造方法 |
CN104524590B (zh) | 2008-04-30 | 2019-06-21 | 伊缪诺金公司 | 交联剂和它们的用途 |
JP2011523628A (ja) | 2008-04-30 | 2011-08-18 | イミュノジェン・インコーポレーテッド | 有効なコンジュゲートおよび親水性リンカー |
CN105175434A (zh) * | 2009-02-05 | 2015-12-23 | 伊缪诺金公司 | 新型苯并二氮杂*衍生物 |
US8431416B2 (en) * | 2009-04-01 | 2013-04-30 | Becton, Dickinson And Company | Reactive heterocycle-substituted 7-hydroxycoumarins and their conjugates |
BRPI1015234A2 (pt) | 2009-06-22 | 2018-02-20 | Medimmune Llc | regiões fc projetadas para conjugação sítio específica. |
WO2011092838A1 (fr) | 2010-01-29 | 2011-08-04 | 株式会社フォーサイド・ドット・コム | Système de partage de contenu et procédé de partage de contenu |
KR102287474B1 (ko) * | 2010-02-24 | 2021-08-06 | 이뮤노젠 아이엔씨 | 엽산염 수용체 1 항체와 면역접합체 및 이들의 용도 |
MY177062A (en) | 2010-03-12 | 2020-09-03 | Debiopharm Int Sa | Cd37-binding molecules and immunoconjugates thereof |
SG10201800757TA (en) | 2010-04-20 | 2018-02-27 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
AU2011320314B2 (en) | 2010-10-29 | 2015-08-06 | Immunogen, Inc. | Novel EGFR-binding molecules and immunoconjugates thereof |
EP2632947A4 (fr) | 2010-10-29 | 2015-03-18 | Immunogen Inc | Molécules non antagonistes se liant au récepteur egf et immunoconjugués de celles-ci |
EP3498303A1 (fr) * | 2011-02-15 | 2019-06-19 | ImmunoGen, Inc. | Procédés de préparation de conjugués |
WO2013177481A1 (fr) * | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazépines et leurs conjugués |
JP6423804B2 (ja) | 2013-02-28 | 2018-11-14 | イミュノジェン・インコーポレーテッド | 細胞結合剤及び細胞毒性剤を含む複合体 |
WO2014134457A2 (fr) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugués comprenant des agents de liaison cellulaire (cba) et des agents cytotoxiques |
EP3566750A3 (fr) * | 2013-02-28 | 2020-04-08 | ImmunoGen, Inc. | Conjugués comprenant des agents de liaison cellulaire et des agents cytotoxiques |
LT3129406T (lt) * | 2014-04-11 | 2019-04-10 | Medimmune, Llc | Konjuguoti junginiai, apimantys inžineriniu būdu sukonstruotus cisteino antikūnus |
WO2015196089A1 (fr) * | 2014-06-20 | 2015-12-23 | Bioalliance C.V. | Conjugués anticorps anti-cd22-médicament et leurs méthodes d'utilisation |
JP2017525755A (ja) * | 2014-06-20 | 2017-09-07 | アブジェノミクス インターナショナル インコーポレイテッド.Abgenomics International Inc. | Her2抗体−薬物抱合体 |
CN106661124A (zh) * | 2014-06-20 | 2017-05-10 | 荷商台医(有限合伙)公司 | 抗叶酸受体α(FRA)抗体‑药物缀合物及其使用方法 |
RU2741470C9 (ru) * | 2014-09-02 | 2021-04-27 | Иммьюноджен, Инк. | Способы составления композиций конъюгата антитело-лекарственное средство |
MA41645A (fr) | 2015-03-04 | 2018-01-09 | Abbvie Stemcentrx Llc | Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation |
US10077313B2 (en) | 2015-06-29 | 2018-09-18 | Immunogen, Inc. | Anti-CD123 antibodies and conjugates and derivatives thereof |
-
2016
- 2016-06-28 HU HUE16738322A patent/HUE052616T2/hu unknown
- 2016-06-28 CN CN202111168673.4A patent/CN113769108A/zh active Pending
- 2016-06-28 LT LTEP16738322.3T patent/LT3313845T/lt unknown
- 2016-06-28 US US15/195,269 patent/US10898579B2/en active Active
- 2016-06-28 AU AU2016285929A patent/AU2016285929B2/en active Active
- 2016-06-28 ES ES16738322T patent/ES2832527T3/es active Active
- 2016-06-28 RU RU2017144859A patent/RU2733740C2/ru active
- 2016-06-28 CA CA2988806A patent/CA2988806A1/fr active Pending
- 2016-06-28 MA MA42250A patent/MA42250B1/fr unknown
- 2016-06-28 RS RS20201354A patent/RS61050B1/sr unknown
- 2016-06-28 EP EP16738322.3A patent/EP3313845B1/fr active Active
- 2016-06-28 CN CN201680038492.0A patent/CN107708810B/zh active Active
- 2016-06-28 PT PT167383223T patent/PT3313845T/pt unknown
- 2016-06-28 KR KR1020187002729A patent/KR20180021176A/ko not_active Application Discontinuation
- 2016-06-28 JP JP2017568292A patent/JP6843080B2/ja active Active
- 2016-06-28 SI SI201630977T patent/SI3313845T1/sl unknown
- 2016-06-28 EP EP20182141.0A patent/EP3769787A1/fr active Pending
- 2016-06-28 WO PCT/US2016/039796 patent/WO2017004025A1/fr active Application Filing
- 2016-06-28 DK DK16738322.3T patent/DK3313845T3/da active
- 2016-06-28 PL PL16738322T patent/PL3313845T3/pl unknown
- 2016-06-28 MD MDE20180452T patent/MD3313845T2/ro unknown
- 2016-06-29 AR ARP160101972A patent/AR106013A1/es unknown
- 2016-06-29 TW TW110132303A patent/TW202146057A/zh unknown
- 2016-06-29 TW TW105120514A patent/TWI740833B/zh active
-
2018
- 2018-10-30 HK HK18113828.1A patent/HK1254782A1/zh unknown
-
2020
- 2020-09-08 US US17/014,404 patent/US20210085800A1/en active Pending
- 2020-11-09 HR HRP20201790TT patent/HRP20201790T1/hr unknown
- 2020-11-10 CY CY20201101058T patent/CY1123606T1/el unknown
-
2021
- 2021-02-19 JP JP2021025322A patent/JP2021088581A/ja active Pending
-
2022
- 2022-03-31 AU AU2022202208A patent/AU2022202208A1/en active Pending
- 2022-08-15 JP JP2022129205A patent/JP7441281B2/ja active Active
-
2024
- 2024-02-16 JP JP2024021646A patent/JP2024067036A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA42250B1 (fr) | Conjugués d'anticorps à cystéine modifiée | |
MA46708B1 (fr) | Anticorps anti-pd1 et leurs utilisations | |
MA44146B1 (fr) | Combinaison d'anticorps anti-pd-1 et d'anticorps bispécifiques anti-cd20/anti-cd3 pour traiter le cancer | |
MA34286B1 (fr) | Compositions pharmaceutiques et procédés pour les fabriquer | |
MA45280B1 (fr) | Conjugués anticorps-médicament à base d'éribuline et leurs procédés d'utilisation | |
BR112018075626A2 (pt) | anticorpos anti-b7-h3 e conjugados de fármaco anticorpo | |
SG10201901825YA (en) | Conjugates comprising cell-binding agents and cytotoxic agents | |
EA202091217A1 (ru) | Конъюгат аналога тубулизина с разветвленными линкерами | |
PH12017500358A1 (en) | Cytotoxic benzodiazepine derivatives | |
SG195172A1 (en) | Novel maytansinoid derivatives with peptide linker and conjugates thereof | |
MX2019005879A (es) | Enlazadores que contienen peptido para conjugados anticuerpo-farmaco. | |
TW201613930A (en) | Cytotoxic benzodiazepine derivatives | |
MA41932B1 (fr) | Méthodes de traitement ou de prévention de migraines | |
SG179163A1 (en) | Novel tricyclic protein kinase modulators | |
MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
MA38567A1 (fr) | Variantes de pertuzumab et leur évaluation | |
MX2019013690A (es) | Conjugados de farmaco-proteina con ciclodextrina. | |
MY183977A (en) | Cytotoxic benzodiazepine derivatives | |
MA42811A (fr) | Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
MA39254B2 (fr) | Anticorps stables à affinité élevée et agrégatifs à base de domaines viraux vl et de dérivé de vhh | |
MX2023010915A (es) | Metodos para preparar ciclooctenos y conjugados de los mismos. | |
MX2020009864A (es) | Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-1. | |
MX2019008773A (es) | Derivados de caliqueamicina y conjugados anticuerpo-farmaco de los mismos. | |
WO2019078697A8 (fr) | Anticorps anti-cd3 et composition pharmaceutique destinée au traitement du cancer, contenant ledit anticorps | |
MA32029B1 (fr) | Vaccins contre la malaria |